Autolus Therapeutics Will Remain Depressed For A While

2025-02-05 07:00:39 ET

Summary

• Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.
• Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising.
• AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt.
• The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years.

Autolus Therapeutics ( AUTL ) is a CAR-T therapy developer that recently got its first approval for obe-cel, branded Aucatzyl, targeting adult r/r B-ALL. As the company tells us, it is the first CAR-T therapy to have been approved without a REMS, highlighting its safety. The company also notes two other differentiating factors:

Novel and differentiated mechanism of action: first and currently only approved CD19 CAR T with a fast off-rate

First and currently only approved CAR T therapy with customized, tumor-burden guided dosing

Read the full article on Seeking Alpha

For further details see: